Autoantibodies to the IGF1 Receptor in Graves' Orbitopathy.Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Köhrle J, Eckstein A, Schomburg L. J Clin Endocrinol Metab. 2013 Feb;98(2):752-60. doi: 10.1210/jc.2012-1771 Graves' disease (GD) is maintained by stimulating antibodies against the TSH receptor. Graves' orbitopathy (GO) is the main extrathyroidal manifestation of GD, potentially involving […]
Archives for February, 2013
NO-Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism.Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS. J Clin Endocrinol Metab. 2013 Feb;98(2):610-7. doi: 10.1210/jc.2012-3125. In the United States, generic substitution of levothyroxine (l-T(4)) by pharmacists is permitted if the formulations are deemed to be bioequivalent by the Federal Drug […]
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. J Clin Endocrinol Metab. 2013 Jan;98(1):31-42 The increasing use of tyrosine kinase inhibitor therapy outside of […]